Fulcrum Equity Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-732
Closed -$204K 96
2025
Q2
$204K Sell
732
-61
-8% -$17.3K 0.21% 99
2025
Q1
$247K Sell
793
-114
-13% -$33.7K 0.27% 79
2024
Q4
$236K Sell
907
-1,081
-54% -$321K 0.23% 94
2024
Q3
$640K Buy
1,988
+14
+0.7% +$4.58K 0.54% 56
2024
Q2
$617K Buy
1,974
+61
+3% +$17.9K 0.55% 58
2024
Q1
$544K Buy
1,913
+54
+3% +$15.8K 0.64% 51
2023
Q4
$535K Sell
1,859
-142
-7% -$38.7K 0.66% 38
2023
Q3
$538K Buy
2,001
+8
+0.4% +$2K 0.63% 44
2023
Q2
$442K Buy
1,993
+369
+23% +$85.6K 0.51% 48
2023
Q1
$393K Buy
1,624
+460
+40% +$113K 0.37% 59
2022
Q4
$306K Buy
1,164
+77
+7% +$20.6K 0.25% 53
2022
Q3
$245K Buy
+1,087
New +$263K 0.21% 55
2022
Q1
Sell
-1,555
Closed -$350K 110
2021
Q4
$350K Sell
1,555
-29
-2% -$6.12K 0.13% 111
2021
Q3
$337K Buy
1,584
+267
+20% +$61.5K 0.13% 119
2021
Q2
$321K Buy
1,317
+117
+10% +$28.8K 0.12% 136
2021
Q1
$299K Sell
1,200
-28
-2% -$6.68K 0.12% 144
2020
Q4
$282K Sell
1,228
-167
-12% -$38.5K 0.11% 134
2020
Q3
$354K Sell
1,395
-1,187
-46% -$294K 0.16% 94
2020
Q2
$609K Buy
2,582
+471
+22% +$107K 0.29% 63
2020
Q1
$428K Sell
2,111
-545
-21% -$119K 0.31% 20
2019
Q4
$640K Sell
2,656
-91
-3% -$20.1K 0.33% 42
2019
Q3
$531K Buy
2,747
+73
+3% +$14K 0.27% 42
2019
Q2
$525K Sell
2,674
-1,480
-36% -$265K 0.25% 41
2019
Q1
$789K Buy
4,154
+6
+0.1% +$1.15K 0.27% 16
2018
Q4
$807K Buy
+4,148
New +$809K 0.3% 16

Other funds holding AMGN

Fulcrum Equity Management's AMGN Position: Q3 2025 in Review

Fulcrum Equity Management sold out of Amgen (AMGN) in Q3 2025, closing a stake of 732 shares — an estimated $204K sold.

Fulcrum Equity Management first reported a position in AMGN in Q4 2018 and held it in 25 quarters. The position peaked at $807K in Q4 2018. 2,819 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.

  • Fulcrum Equity Management reported no remaining Amgen position as of Q3 2025 after selling out during the quarter.
  • Fulcrum Equity Management sold 732 Amgen shares in Q3 2025, an estimated $204K.
  • Fulcrum Equity Management first reported a position in Amgen in Q4 2018 and held it in 25 quarters.
  • Fulcrum Equity Management's Amgen position peaked at $807K in Q4 2018.
  • 2,819 funds tracked by Wall St. Rank held Amgen as of Q3 2025.

Based on Fulcrum Equity Management's 13F filing for Q3 2025, filed 6 Jan 2026.